4//SEC Filing
Mann David A 4
Accession 0001209191-10-052020
CIK 0001298521other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 6:04 PM ET
Size
17.9 KB
Accession
0001209191-10-052020
Insider Transaction Report
Form 4
Mann David A
Director
Transactions
- Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $3.45Exp: 2020-05-26→ Common stock (5,000 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−19,135→ 0 totalExercise: $8.34Exp: 2016-04-21→ Common stock (19,135 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $2.28Exp: 2019-05-27→ Common stock (5,000 underlying) - Disposition to Issuer
Common Stock
2010-10-28−12,935→ 0 total - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $19.08Exp: 2017-05-25→ Common stock (5,000 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $6.63Exp: 2018-05-28→ Common stock (5,000 underlying)
Footnotes (6)
- [F1]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $17,656.28 cash, (b) 2,122 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 12,935 contingent value rights, which represent the right to receive possible additional cash payments.
- [F2]This option, which was 100% vested on April 21, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F3]This option, which was 100% vested on May 27, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F4]This option, which was 100% vested on May 15, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F5]This option, which was 100% vested on May 26, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $11,350, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F6]This option, which was to be 100% vested on May 25, 2011, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $5,500, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments.
Documents
Issuer
Trubion Pharmaceuticals, Inc
CIK 0001298521
Entity typeother
Related Parties
1- filerCIK 0001366316
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 6:04 PM ET
- Size
- 17.9 KB